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ABSTRACT 
Objective: The aim of the study is to formulate and evaluate the topical preparations of antibacterial formulation for the treatment of diabetic 
wound infection.  
Methods: Different types of topical formulations were prepared and evaluated for in vitro release. The prepared formulations were also tested for 
its antibacterial activity against the pathogens existing in diabetic wound infection. Based on in vitro drug release and antimicrobial activity, two 
formulations were selected as optimized formulations. Optimized formulations were tested for wound healing activity in diabetic rats.  
Results: Based on in vitro drug release and antimicrobial activity two formulations (F8, F10) were selected as optimized formulations. FTIR studies 
of pure drug and optimized formulation shown absence of any incompatibility between drug and excipients. Optimized formulation shown good 
physicochemical properties and passed short-term stability study. F8 and F10 formulations were applied to untreated diabetic rats for diabetic 
wound infection, the rate of wound healing was quite faster. These results indicate that the linezolid semisolid dosage form could provide an 
adjunctive antimicrobial formulation for the management of diabetic wounds. 
Conclusion: Further studies are required on chronic diabetic wounds with and without diabetic medications to confirm its effectiveness.  
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INTRODUCTION 
Diabetes mellitus is globally prevalent, diabetic wound and ulcer is 
one of its most severe and expensive complications. Diabetic wound 
and ulcer results from an intricate interaction of a number of risk 
factors. Patients with diabetic wound and ulcers often require 
amputations of the lower limbs and, in more than half the cases, 
infection is the preeminent factor [1]. Human skin comprises of 
protective layers and once the protective layer of skin is damaged, 
deep tissues are exposed to bacterial infection [2]. Streptococcus 
aureus is a bacterium which predominantly causes skin infection. 
Linezolid is the drug of choice for the treatment of the methicillin-
resistant Streptococcus aureus (MRSA). Linezolid is the first synthetic 
antibiotic which belongs to a new class of antibiotics called the 
oxazolidinones. Linezolid inhibits protein synthesis by binding with 
the 50S ribosomal subunit thereby hindering the bacterial growth. 
Oral, as well as intravenous dosage forms of linezolid, are available for 
the treatment of MRSA. The present treatment for diabetic wound 
infections are mostly oral or IV antibiotic formulations. Failure in 
patients following and adhering to the right treatment leads to 
deteriorating the condition of diabetic wound infections. 
Favorable results were noted by a number of studies using oral or 
intravenous linezolid for the treatment of soft tissue, bone, and joint 
infections. These factors make it a possible substitute for local 
antibiotic therapy in diabetic wound infections [3]. 
With these literature data, we have planned to formulate linezolid 
semisolids which may be beneficial and can be a possible adjuvant 
for local antibiotic therapy in diabetic patients from worsening of 
the diabetic wound and amputation of lower limbs. Semisolid dosage 
forms leads to more patient compliance along with existing oral and 
IV dosage form and hence patient may adhere to the treatment 
leading to better success in the treatment. 
MATERIALS AND METHODS 
Materials 
Linezolid was procured from the Glenmark Generics Limited, Gujarat. 
Streptozotocin MP Biomedicals, LLc. All other excipients used were of 
analytical grade. All animal experimental procedures were approved 
by IAEC, Manipal (Reference No. IAEC/KMC/16/2014 dated January 
27, 2014). 
Drug-excipient compatibility studies  
Drug–excipient compatibility studies were conducted for optimized 
formulation by Fourier Transmitter Infrared (FTIR) and Differential 
Scanning Calorimetry (DSC) [5]. 
Infrared spectroscopy 
Infrared spectra were recorded using a Shimadzu FTIR 8300 
spectrophotometer and the spectrum was recorded in the region of 
4000 to 400 ܿ݉−1.  
Differential scanning calorimetry  
Pure drug sample and optimized formulations were studied for DSC. 
DSC was performed using DSC-60, Shimadzu, Japan. The samples were 
placed in a sealed aluminum pan, before heating under nitrogen flow 
(30 ml/min) at a scanning rate of 5 °C/min from 30 °C to 300 °C.  
Formulation and evaluation 
Preparation of different semisolid formulations 
Preparation of cream 
Linezolid creams were prepared as per the composition is given in 
table 1. The required amount of lipids were weighed and kept for 
melting at 70 °C. Simultaneously, the aqueous phase was also kept 
for heating and was added slowly to lipid phase while mixing until it 
congealed. The drug was ground by using mortar and pestle. The 
powdered drug was levigated with the same volume of cream and 
mixed thoroughly to get a homogenized mixture. 
Preparation of ointment  
Linezolid ointments were prepared as per the composition is given 
in table 2 and table 3 by employing fusion method [6]. In this 
method the constituents of the base like stearyl alcohol, white soft 
paraffin, emulsifying wax and cetyl alcohol (solid ingredients) 
were placed together in the beaker and allowed to melt together at 
70 °C. After melting, other ingredients were mixed and stirred 
gently during cooling stage. Formulation of ointment was done by 
including the active ingredient in the base by trituration using 
mortar and pestle. 
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Table 1: Composition of linezolid creams 
Ingredients Quantity in g for 10 grams formulation 
 F1 F2
Linezolid 0.1 0.1
Aqueous phase 
Benzoic acid 0.02 0.02 
Sorbitol 0.3 0.8 
Sodium lauryl sulphate 0.10 0.10 
Tween 80 0.046 0.025 
Sodium acetate buffer 3.0 ml 3.0 ml 
Oil phase 
White bees wax 3.08 2.48 
Cetyl alcohol 0.3 0.3
Mineral oil 2.9(3.41 ml) 3. (3.52 ml) 
Span 60 0.154 0.175 
 
Table 2: Composition of linezolid ointments F3, F4 and F5 
Ingredients Quantity in g for 10 grams formulation
 F3 F4 F5
Linezolid 0.1 0.1 0.1 
Emulsifying wax 0.8 - 3.0
White soft paraffin 8.5 2.4 5.0
Liquid paraffin - - 1.0 
Cetyl alcohol - - 0.3 
Stearyl alcohol 0.3 2.5 0.3
Benzoic acid - - 0.02
Methyl paraben - 0.1 - 
Polyethylene glycol-400 - 1.2(1.06 ml) - 
Cholesterol 0.3 - - 
Sodium acetate buffer - 3.7 ml - 
Zinc stearate - - 0.28 
 
Table 3: Composition of linezolid ointments F6, F7 and F8 
Ingredients Quantity in g for 10 grams formulation 
 F6 F7 F8 
Linezolid 0.1 0.1 0.1 
Polyethylene glycol-400 6.0 5.0 4.0 
Polyethylene glycol-4000 2.0 3.0 2.0 
Propylene glycol 1.9 1.88 2.05 
Isopropyl myristate - - 0.8 
Methyl paraben - 0.02 0.02 
 
Table 4: Composition of linezolid gel F9 and F10 
Ingredients Quantity in g for 10 grams formulation
 F9 F10 
Linezolid 0.1 0.1 
HPMC ELV5 - 0.6 
Carbopol 934 0.5 0.3
Triethanolamine q. s. q. s.
Propylene glycol 3.4 2.0 
Glycerol 3.0 - 
Sodium acetate buffer 3.0 7.0 ml
 
Preparation of gel  
Linezolid gels were prepared as per composition is given in table 4 
[7, 8]. The required amount of carbopol was weighed and soaked in 
7.0 ml of buffer for 2h. Then hydroxypropyl methyl cellulose (HPMC 
ELV5) was dissolved in remaining buffer and added to carbopol 934 
and the drug in propylene glycol also added to gel system. 
Triethanolamine was used to neutralize and adjust the pH of the gel 
system. The drug concentration in all formulations was kept 
constant at 1 % w/w. Propylene glycol was used as co-solvent and as 
a dispersion medium for the linezolid. Carbopol and HPMC at a ratio 
of 1:2 were prepared. HPMC was added to carbopol to improve the 
physical properties, viscosity, and yield of the gel product. 
Physicochemical evaluation of the formulations  
The spreadability, pH and viscosity of the prepared formulations 
were performed according to the standard procedures and the 
results were noted [9]. 
Spreadability 
Spreadability of the optimized formulations was tested against standard 
weight applied on the glass sample plate and measuring the area of the 
sample. The spreadability (S) was calculated using the formula:  
ܵ = m.lt  where S=spreadability, m=weight, l=spreaded area on the 
glass slide, t = time s. 
Rathnanand et al. 
Int J App Pharm, Vol 8, Issue 3, 2016, 30-36 
32 
pH 
The pH of the formulations was recorded by making suspension of 
the formulations by dissolving 1 g of the formulation in 10 ml of 
distilled water. The pH was measured by digital pH meter 
Viscosity 
Viscosities of the optimized formulations were measured by using 
Brookfield Viscometer (LVDV-II) by using spindle number 27. The 
measurements were done at room temperature over the range of 
speed starting from 10, 20, 40, 60, 80 and 100 rpm. 
Drug content estimation 
1g of cream was weighed and dissolved in 100 ml of buffer and filtered 
through Whatman filter paper. From the filtrate 1 ml of sample was 
pipetted out and diluted to 10 ml with buffer to get a clear solution. Then 
the sample was analyzed in UV spectrophotometer, keeping the base 
solution without drug as blank and absorbance was noted. 
Zone of inhibition studies  
These studies were carried out by using pour plate method to 
identify the formulation activity against bacterial culture in required 
medium. 12h old cultures of Staphylococcus aureus, Escherichia coli, 
Pseudomonas aeruginosa were used for this study by using nutrient 
agar medium [10, 11]. 
In vitro diffusion studies for formulations  
Diffusion cell was used for performing in vitro diffusion studies. 1g 
of the formulation was placed in the donor compartment, 30 ml of 
buffer was placed in the receptor compartment, and the two 
compartments were separated by using a sigma membrane.5 ml of 
sample was withdrawn at time intervals of 10, 20, 30, 40, 50 and 60 
min. The temperature was maintained at 32 ℃ [12]. 
Animal studies  
Male Sprague-Dawley rats (average body weight 280±40g) were 
opted to induce diabetes [13, 14]. 
Induction of diabetes 
Rats were fasted for 12h and a single intraperitoneal injection of 40 
mg/kg of streptozotocin was given for the induction of diabetes. 
Animals whose blood glucose level exceeded 200 mg/dl at 24h after 
treatment were considered diabetic [15, 16] 
Wound model  
Excision wound 
The diabetic rats were anesthetized by injecting ketamine solution 
(0.3 ml) through I. P. Excision wound was imposed by cutting away 
450 mm2full thickness of a determined area of the depilated back of 
each diabetic rat. Epithelization period was noted as the number of 
days after wounding required for the scar to fall off leaving no raw 
wound behind [15]. 
Measurement of wound healing 
Wound shrinkage rate was measured by planimetric measurement 
of the wound area every alternative day. Two Sprague-Dawley rats 
received marketed formulation containing framycetin sulphate 1% 
w/w as a reference and the remaining rats received optimized 
formulation of ointment and gel.  
Stability studies  
Stability studies of the optimized formulations were conducted. ICH 
real time stability studies at 25 °C/60% & 40 ° C/75% RH for a 
period of 1 mo. The samples were filled in a plastic box. The samples 
were withdrawn at the end and tested for appearance and drug 
content [16]. 
RESULTS AND DISCUSSION 
Drug excipient compatibility studies 
FTIR studies 
FTIR spectra of pure drug and formulations are shown in fig. 1, 2 
and 3. Most of the peaks are retained by the formulations. Some 
peaks have shown decreased intensity or broadening might be due 
to physical interactions with excipients which would not affect its 
release from the formulations. 
Differential scanning calorimetry 
DSC results also showed no interaction between drug and excipients. 
Physicochemical evaluation of formulations 
Spreadability test 
Spreadability value for F8 and F10 is given in table 5. 
 
 
Fig. 1: Infrared spectroscopy of linezolid pure drug 
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Fig. 2: Infrared spectroscopy of linezolid–ointment formulation 
 
 
Fig. 3: Infrared spectroscopy of linezolid-gel formulation 
 
Table 5: Spreadability value for F8 and F10 
Formulation code Average diameter(cm) Radius (r) Area=πr2 S=࢓.࢒࢚  (g. cm2/s) 
F8 4.13 2.06 13.34 44.47 
F10 5.1 2.55 20.41 68.33 
* n=3, Average of three determinations 
 
F10 gel has shown more spreadability compared to F8 ointment 
formulation. The spreadability values indicate that the formulation 
can easily applied onto the skin.  
pH 
pH of all the formulations (F1-F10) are shown in table 6  
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Table 6: pH of all the formulations (F1–F10) 
Formulation pH 
F1 6.1
F2 6.2 
F3 6.6 
F4 6.2
F5 6.0
F6 5.8  
F7 5.9 
F8 4.6
F9 5.0
F10 5.1 
* n=3, Average of three determinations 
 
Both F8 and F10 formulations showed optimum pH value, which 
was equal to the pH of skin at the site of the diabetic wound. So the 
drug diffusion will be more with this pH.  
Viscosity 
Viscosity at different shear rates for both formulations has shown in 
table 7. 
 
Table 7: Viscosity values of F8 and F10 formulations 
Revolutions per minute Centipoise  
F8 F10
10 87200 75200
20 61380 44467
40 46780 27133 
60 21450 20067 
80 16570 16117
100 14690 13420
* n=3, Average of three determinations 
 
As shear and stress increases the viscosity of formulation decreases. 
A formulation containing PEG (F8) showed better viscosity and 
stability. Formulations containing carbopol: HPMC (1:2) (F10) gave 
a gel of highest viscosity structure and best drug diffusion. The long 
residence time of the gel combined with the ability of the gel to 
release the drug in the sustained matter will assist in enhancing 
bioavailability. Change in the ratio of the incorporation of the two 
polymers affects the rheological behavior and the release profile of 
the drug from the gel. 
Drug content 
Drug content of all the formulations are shown in table 9. 
 
Table 9: Drug content of prepared different formulations 
Formulation Average drug content (mg/1g of the formulation) 
F1 3.04±0.130 
F2 5.19±0.500 
F3 1.18±0.049 
F4 9.21±0.140 
F5 5.34±0.499 
F6 9.34±0.100 
F7 9.67±0.4 
F8 10.13±0.39 
F9 5.41±0.131 
F10 9.19±0.138 
* n=3, Average of three determinations  
 
Not all the formulations showed theoretical concentration (1% 
w/w) of drug content. Only F8 showed theoretical value. F3 showed 
very less drug content, due to high forces of drug entrapment in the 
semisolid base. 
Zone of inhibition 
The zone of inhibition of pure drug against Staphylococcus aureus is 
given in fig. 4 and the zone of inhibition values of different 
formulations against Streptococcus aureus are given in table 8. 
 
 
Fig. 4: Zone of inhibition of pure drug against Staphylococcus 
aureus 
 
Table 8: Zone of inhibition of different formulations against 
Staphylococcus aureus 
Formulation code  Zone of inhibition (mm) 
Pure drug  26 
F1 26 
F2 28 
F4 34 
F5 30 
F6 32 
F7 36 
F8 40 
F9 30 
F10 38 
* n=3,±SD 
 
In vitro diffusion studies 
For all the formulations three batches were taken for diffusion study (n = 
3) and average value with standard deviation is reported in table 10. 
Formulation F8 showed maximum drug release (24.97%) at 60thmin. 
F8 had optimum concentration of PEG 400(40%) and penetration 
enhancer’s propylene glycol and isopropyl myristate. The zone of 
inhibition with staphylococcus aureus also found to be 40 mm which 
was highest compared to all other formulations. Formulation F10 
showed maximum drug release (23.43%) at 60th min due to the 
presence of both carbopol and HPMC (1:2). Zone of inhibition was 
found to be 38 mm and pH of was 5.1, which is the pH at the diabetic 
wound site. 
Animal studies 
For 16 rats we induced diabetes by injecting streptozotocin 45 
mg/kg body weight through Intraperitoneal route (I. P). From those 
only 7 rats showed required glucose (diabetic range) level and those 
animals were taken for further studies. 
Blood glucose levels 
Blood glucose levels of fasting 12 h rats were recorded by using 
accu-chek sensor glucometer and were noted as shown in table 11. 
Wound area measurement 
Initial wound area created was 450 mm2. The wound area of 
individual rats was measured by tracing the wound on graph paper 
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and counting the squares (1 mm2) in that area. The data of wound 
area measurement is shown in table 12. Results shows that order of 
wound healing was faster with formulation F10, F8 and reference 
formulation respectively. Fig. 5 depicts rat with the initial wound, 
fig. 6 depicts rat with a wound on fifteen days of treatment and fig. 8 
depicts rat after seventeenth day of treatment F10 formulation. 
 
Table 10: % Cumulative drug release of linezolid formulations 
Media Time 
in 
minute
s 
% Cumulative drug release  
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
 
0.1M 
Sodiu
m 
Acetat
e 
Buffer 
0 0 0 0 0 0 0 0 0 0 0 
10 1.50±0.0
7 
1.01±0.1
3 
0.24±0.13 1.54±0.1
3 
1.17±0.1
0 
0.36±0.27 3.83±0.56 5.06±0.67 2.05±0.20 4.83±0.41
20 2.24±0.0
3 
1.33±0.0
5 
0.42±0.08 2.83±0.1
2 
1.95±0.1
2 
1.17±0.20 6.33±0.30 8.45±0.32 3.1763±0.0
8 
8.36±1.13 
30 2.91±0.1
1 
2.80±0.0
6 
0.52±0.43 3.81±0.1
1 
3.66±0.1
6 
4.15±0.61 10.37±0.4
6 
13.86±0.9
7 
3.4152±0.0
9 
14.77±1.2
6 
40 3.21±0.1
6 
3.55±0.0
4 
0.73±0.09 4.17±0.2
1 
4.79±0.0
8 
9.73±0.41 14.40±0.1
6 
17.45±0.3
4 
3.7082±0.0
8 
18.58±0.6
4 
50 3.60±0.0
8 
4.65±0.0
5 
0.93±0.02 4.46±0.0
6 
5.43±0.2
2 
14.80±0.4
0 
18.98±0.6
2 
26.86±0.4
1 
4.7918±0.1
31 
19.77±0.1
6 
60 4.51±0.1
6 
6.46±0.0
9 
1.421±0.0
2 
4.52±0.0
8 
6.55±0.1
1 
20.18±0.4
8 
21.51±0.3
6 
24.96±0.6
1 
5.0674±0.0
6 
23.43±0.3
6 
* n=3,±SD 
 
Table 11: Blood glucose levels 
Rats with code and formulation Blood glucose levels(mg/dl) 
F8 268 
F10 335 
Reference formulation 214
 
Table 12: Wound area measurement 
Rat with formulation 
code 
Day Initial wound area 
(mm2) 
Specific day wound 
area(mm2) 
% wound healing 
(࢏࢔࢏࢚࢏ࢇ࢒ ࢝࢕࢛࢔ࢊି࢙࢖ࢋࢉ࢏ࢌ࢏ࢉ ࢊࢇ࢟ ࢝࢕࢛࢔ࢊ࢏࢔࢏࢚࢏ࢇ࢒ ࢝࢕࢛࢔ࢊ ×100) 
F 8 0  
450 
0 0
5 314 30.2 
10 132 70.66 
15 22 95.11 
17 1 99.77
F 10 0 0 0
5 275 38.88 
10 141 68.66 
15 16 96.44
17 0 100
Reference formulation 0 0 0 
5 334 25.77 
10 185 58.88
15 40 91.11 
17 23 94.88 
* n=3, Average of three determinations, F 10 formulation showed better wound healing rates compared to F 8 and reference formulation. 
 
 
Fig. 5: Rat with initial wound 
 
Fig. 6: Rat with wound after 15th day of treatment with F10 
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Fig. 7 Rat after 17th day of treatment 
 
Stability studies 
F8 formulation got liquefied at higher temperature and humidity. 
For F10 formulation evaporation of water was observed at higher 
temperature and humidity. There was no color change observed 
under higher temperature and humidity conditions. But both the 
formulations were stable at the low temperatures. This suggests that 
these formulations are to be stored in airtight container under cool 
conditions, protected from light. Further, long-term stability studies 
may provide precise required storage conditions. 
CONCLUSION 
These results indicate that linezolid semisolid dosage form could 
provide an adjunctive antimicrobial formulation for the 
management of diabetic wounds. Further studies are required on 
chronic diabetic wounds with and without diabetic medications to 
confirm its effectiveness. 
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